Medical Health & Life Science Research News

Learn details of the global hepatocellular carcinoma drugs pipeline developement therapeutics

Learn details of the global hepatocellular carcinoma drugs pipeline developement therapeutics

Hepatocellular Carcinoma drugs Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma drugs, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.Hepatocellular Carcinoma pipeline guide helps in identifying and tracking emerging players in the market and their portfolios.

- Agency -.

Hepatocellular Carcinoma Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. Hepatocellular Carcinoma is cancer that starts in the endometrium, the lining of the uterus (womb).

- Agency -.

Hepatocellular Carcinoma is the most common type of uterine cancer.

Report: www.reportsnreports.com/contacts/.aspx?name=1057909

Description of Report:

Hepatocellular Carcinoma Pipeline Review H1 2017 reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Phase 0 stages are 5, 2 and 1 respectively.

Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report features investigational drugs from across globe covering therapy areas and indications.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Key Companies Analyzed In Report:

AB Science SA, AbbVie Inc, Abivax SA, Acceleron Pharma Inc, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, Alfact Innovation, Amgen Inc, AndroScience Corp, ArQule Inc, Array BioPharma Inc, AstraZeneca Plc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Bio-Cancer Treatment International Ltd, Biomics Biotechnologies Co Ltd, Bioneer Corp, Blueprint Medicines Corp, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd, CASI Pharmaceuticals Inc, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celldex Therapeutics Inc, Celsion Corp, China Medical System Holdings Ltd, Chugai Pharmaceutical Co Ltd, Conatus Pharmaceuticals Inc, Delcath Systems Inc, Dicerna Pharmaceuticals Inc, Double Bond Pharmaceutical International AB, eFFECTOR Therapeutics Inc, Eiger BioPharmaceuticals Inc, Eisai Co Ltd, Eli Lilly and Company, Endocyte Inc, Epeius Biotechnologies Corp, eTheRNA Immunotherapies NV, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, Galaxy Biotech LLC, Genelux Corp, Genoscience Pharma, Genosco Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Golden Biotechnology Corp, Green Cross Cell Corp, Green Cross Corp, H3 Biomedicine Inc, HanAll Biopharma Co Ltd, Horizon Pharma Plc, Humorigin Biotechnology Corp, Immatics Biotechnologies GmbH, Immune Therapeutics Inc, Immunicum AB, Immunitor Inc, Immunomedics Inc, Immunovative Therapies Ltd, In-Cell-Art SAS, Incyte Corp, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, InteRNA Technologies BV, Jenrin Discovery Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, KAHR medical Ltd, Karcinolys SAS, Kite Pharma Inc, Komipharm International Co Ltd, Kowa Company Ltd, Les Laboratoires Servier SAS, Ligand Pharmaceuticals Inc, Lixte Biotechnology Holdings Inc, MaxCyte Inc, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Midatech Pharma Plc, Millennium Pharmaceuticals Inc, Mina Therapeutics Ltd, MTG Biotherapeutics Inc, MultiCell Technologies Inc, NeuroVive Pharmaceutical AB, NormOxys Inc, Novartis AG, NovaTarg Therapeutics Inc, Nymox Pharmaceutical Corp, Omeros Corp, Oncolys BioPharma Inc, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oneness Biotech Co Ltd, Ono Pharmaceutical Co Ltd, Onxeo SA, Otsuka Holdings Co Ltd, Panacea Pharmaceuticals Inc, PepVax Inc, Peregrine Pharmaceuticals Inc, Pfizer Inc, Pharma Mar SA, PharmAbcine Inc, PharmaEssentia Corp, Provecs Medical GmbH, Provectus Biopharmaceuticals Inc, Q BioMed Inc, RedHill Biopharma Ltd, Regulus Therapeutics Inc, Saronic Biotechnology Inc, Shenogen Pharma Group Ltd, Sillajen Biotherapeutics, Simcere Pharmaceutical Group, Sun Pharma Advanced Research Company Ltd, Taiwan Liposome Company Ltd, Takeda Pharmaceutical Company Ltd, TC BioPharm Ltd, tella Inc, Tessa Therapeutics Pte Ltd, Therapure Biopharma Inc, Theravectys SA, Threshold Pharmaceuticals Inc, Tiziana Life Sciences Plc, TRACON Pharmaceuticals Inc, Tumorend LLC, UbiVac LLC, VasGene Therapeutics Inc, Vaxon Biotech, Vect-Horus SAS, Verlyx Pharma Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, Yooyoung Pharm Co Ltd

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage

Report: www.reportsnreports.com/contacts/.aspx?name=1057909

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma. Identify potential new clients or partners in the target demographic.

Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.

Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Major Table OF Content

  • Number of Products under Development for Hepatocellular Carcinoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Hepatocellular Carcinoma - Pipeline by AB Science SA, H1 2017
  • Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Abivax SA, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Acceleron Pharma Inc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Amgen Inc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H1 2017
  • Hepatocellular Carcinoma - Pipeline by ArQule Inc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Bayer AG, H1 2017
  • Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H1 2017
  • Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017

Access Report Complete Pdf Report of 71 Pages with 21 Tables and 10 Figures: www.reportsnreports.com/.aspx?name=1057909

 

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.